Corticosteroid Use Declines in Patients With IBD Over Past 20 Years
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Reviewing a patient’s potential risk for osteoporosis should be a routine part of each visit for patients with IBD.
Investigators examined the effects of spirulina on anthropometric parameters, blood pressure, and quality of life measures in patients with ulcerative colitis.
Investigators aimed to characterize the systemic, preclinical inflammatory immune response of UC using a comprehensive set of proteins.
Due to the relatively high relapse rate and need for additional therapies, current research is being done on the use of Vedolizumab for the treatment of microscopic colitis.
A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
Researchers aimed to better elucidate the role of fDPP-4 levels as a biomarker of IBD activity and to correlate it with certain clinical parameters.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.